Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus rating of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $981.71.

REGN has been the subject of a number of recent analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $969.97 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market cap of $106.46 billion, a PE ratio of 28.65, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. The stock has a 50-day moving average of $942.67 and a 200-day moving average of $899.44. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $998.33.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph J. Larosa sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the sale, the executive vice president now directly owns 37,543 shares of the company’s stock, valued at approximately $36,328,483.95. The disclosure for this sale can be found here. Insiders sold 8,095 shares of company stock valued at $7,779,766 in the last quarter. 8.83% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 8,391 shares of the biopharmaceutical company’s stock worth $6,905,000 after purchasing an additional 42 shares during the last quarter. Stratos Wealth Partners LTD. grew its holdings in shares of Regeneron Pharmaceuticals by 29.4% during the third quarter. Stratos Wealth Partners LTD. now owns 466 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 106 shares during the last quarter. Advisor Partners II LLC grew its holdings in shares of Regeneron Pharmaceuticals by 11.0% during the third quarter. Advisor Partners II LLC now owns 3,190 shares of the biopharmaceutical company’s stock worth $2,625,000 after purchasing an additional 317 shares during the last quarter. Park Avenue Securities LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $1,176,000. Finally, Catalyst Financial Partners LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $235,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.